Dimerix, Takeda in GPCR Screening Pact | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Dimerix Bioscience said today that it will help Takeda Cambridge Limited study G-protein coupled receptors (GPCR) that Takeda believes may be developed into drug compounds.

Under the agreement, Australia-based Dimerix will use its GPCR-HIT platform to form complexes called heteromers that can be used to screen for and profile compounds for Takeda Cambridge, which is a UK-based subsidiary of Japan's Takeda Pharmaceutical.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.